Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
about
Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B.YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation.Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma.Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B.Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers.Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B.Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region.Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study.Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations.Icteric flare of chronic hepatitis B in a 95-year old patient.On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination.Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B.Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China.Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B.Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese.Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B.
P2860
Q34173092-37A3FD3D-01FA-4ECE-BCF5-59BB9804BEFFQ35011213-7D3A32A9-7697-42A9-99A8-B5AA7998DDCDQ37214128-7BA53308-2FE7-4C62-A3EE-B333A181DDEBQ40441364-83D0F6B8-65AB-475D-A23C-164BF41338E0Q40528074-35260BD3-AE81-4F98-87EB-7E6929EF9069Q40537499-48AB601C-3741-4975-9C59-2F092988788AQ41157144-154AF4A8-CAE5-4379-B3E0-4076332D7D27Q41788195-D16D3DFA-F543-4ED9-86C3-CBDD85AF8D09Q42151600-D4D839C4-9377-4F9E-A5E1-5AAEE84FFC2DQ42181000-6169AE93-198B-4FFC-8DFE-703BBEE33A58Q42232725-0679A20A-9A49-4CAE-BEB3-5F3C9D362A77Q42243094-BB878F3C-2B9D-478B-B637-48AC36C3E561Q42262667-BB70E166-311C-4E7B-907F-4F9093BC0E40Q42285772-63F71FA4-F452-42DF-B5F9-53369C0A1FABQ42287464-4B6271F7-CF45-4D05-AD21-0E1B91454C38Q43139834-AD195A4E-7658-4966-AF3D-D1C224DDAF71Q43565728-8F95E440-7681-424E-8534-98610012326DQ44535161-FDAF0645-965A-4942-B79D-C5334D998FADQ44895107-CEE62704-4F8D-4865-8B91-F43F13162091Q45250862-D30D867D-9D1A-4F0F-AA23-C38997C84324Q45364825-FFFD3FA6-B9C0-4E9E-90B6-D76C4E92B0C5Q45397200-39027507-5849-4035-8E34-3AA012064BE7Q45422025-01FB823B-D477-4968-B155-56C06C4BAD3BQ51139539-F785D01D-2A49-4683-A048-AB6A42133480Q51414931-B972CF4F-7180-4A76-8CD3-86BF38CCE184Q54319962-AF6DE59A-5BA2-4C39-A6FA-0AEEE52F0244
P2860
Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Factors associated with viral ...... e after liver transplantation.
@en
Factors associated with viral ...... e after liver transplantation.
@nl
type
label
Factors associated with viral ...... e after liver transplantation.
@en
Factors associated with viral ...... e after liver transplantation.
@nl
prefLabel
Factors associated with viral ...... e after liver transplantation.
@en
Factors associated with viral ...... e after liver transplantation.
@nl
P2093
P2860
P356
P1476
Factors associated with viral ...... e after liver transplantation.
@en
P2093
Albert Ka-Keung Chui
Araga Ramesha Nitin Rao
Chi-Hang Tse
Francis Ka-Leung Chan
Henry Lik-Yuen Chan
Joseph Jao-Yiu Sung
May-Ling Wong
Wan-Yee Lau
P2860
P304
P356
10.1002/JMV.10185
P577
2002-10-01T00:00:00Z